These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576 [No Abstract] [Full Text] [Related]
9. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218). Lambert JS; McNamara J; Katz SL; Fenton T; Kang M; VanCott TC; Livingston R; Hawkins E; Moye J; Borkowsky W; Johnson D; Yogev R; Duliege AM; Francis D; Gershon A; Wara D; Martin N; Levin M; McSherry G; Smith G J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):451-61. PubMed ID: 9859958 [TBL] [Abstract][Full Text] [Related]
10. Update on HIV vaccines. Meldorf M; Corey L STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929 [TBL] [Abstract][Full Text] [Related]
11. Developing an HIV vaccine. Haynes BF; Burton DR Science; 2017 Mar; 355(6330):1129-1130. PubMed ID: 28302812 [No Abstract] [Full Text] [Related]
13. Prime-boost immunization strategies against HIV. Barnett SW; Klinger JM; Doe B; Walker CM; Hansen L; Duliège AM; Sinangil FM AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S299-309. PubMed ID: 9814958 [No Abstract] [Full Text] [Related]
14. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275 [TBL] [Abstract][Full Text] [Related]
15. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees. Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879 [TBL] [Abstract][Full Text] [Related]
16. Poxvirus vector-based HIV vaccines. Pantaleo G; Esteban M; Jacobs B; Tartaglia J Curr Opin HIV AIDS; 2010 Sep; 5(5):391-6. PubMed ID: 20978379 [TBL] [Abstract][Full Text] [Related]
17. Update on HIV vaccines: which way now? Stevceva L Curr Med Chem; 2011; 18(26):3952. PubMed ID: 21824097 [No Abstract] [Full Text] [Related]
18. Turning a corner on HIV neutralization? Nunberg JH; Follis KE; Trahey M; LaCasse RA Microbes Infect; 2000 Feb; 2(2):213-21. PubMed ID: 10742693 [TBL] [Abstract][Full Text] [Related]
19. Potential risks of eliciting antibodies enhancing HIV-1 infection of monocytic cells by vaccination with V3 loops of unmatched HIV-1 isolates. Jiang S; Neurath AR AIDS; 1992 Mar; 6(3):331-2. PubMed ID: 1567580 [No Abstract] [Full Text] [Related]
20. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]